Stavzor Articles

Abbott ups forecast on better-than-expected third quarter results

15 October 2009

TopoTarget says failed Aguvane study was worthwhile

30 March 2009

Tentative FDA appro for Noven's Stavzor

7 January 2008

TopoTarget gets key US and European patents

10 December 2007

Noven gets FDA "approvable letter" for Stavzor

29 October 2007

Noven to buy JDS Pharma in $125M deal

26 July 2007

TopoTarget initiates Ph II with Avugane

30 April 2007

TopoTarget buys Apoxis for $19.5M

16 April 2007

Epilepsy drug shows promise as cancer therapy

22 May 2006

TopoTarget's PEAC gets Orphan Drug status

18 July 2005

TopoTargets gets US and EU patents

6 June 2005

Studies reveal risk of birth defects from AEDs

13 September 2004

Janssen-Cilag's topiramate expected to grow migraine prevention market

29 September 2003

Shire makes milestone payment to D-Pharm for anticonvulsant

11 March 2002

Abbott strengthens label for epilepsy drugs

7 August 2000

D-Pharm and Shire link up for epilepsy compound

16 March 2000

-D-Pharm starts Phase I trials of DP-VPA

22 April 1999

Chiesi Aims For Top 20 Place In Italian Market

5 August 1998

Israel's D-Pharm Raises $6 million From Placing

7 April 1997

ABPI Highlights Advances In Epilepsy Treatment

6 May 1996

Higher-Priced Drugs Set To Expand Epilepsy Market

12 February 1996

Abbott's Divalproex Gains 3rd Indication In USA

12 June 1995

FDA Panel Backs Abbott's Depakote For Bipolar Illness

13 February 1995

Abbott Submits NDA For Zileuton

26 September 1994

EPILIM CHRONO LAUNCH IN UK

27 September 1993

FARMITALIA PRODUCT LAUNCH

22 March 1993

Showing 1-26 of 26 articles

Go to beginningPrevious
  • 1
NextGo to end